83 related articles for article (PubMed ID: 3034324)
1. Serial urinary cyclic guanosine monophosphate measurements in the assessment of response to treatment in epithelial ovarian cancer.
Luesley DM; Chan KK; Newton JR; Blackledge GR
Br J Obstet Gynaecol; 1987 May; 94(5):461-6. PubMed ID: 3034324
[TBL] [Abstract][Full Text] [Related]
2. Random urinary cyclic 3',5' guanosine monophosphate in epithelial ovarian cancer: relation to other prognostic variables and to survival.
Luesley DM; Blackledge GR; Chan KK; Newton JR
Br J Obstet Gynaecol; 1986 Apr; 93(4):380-5. PubMed ID: 3008807
[TBL] [Abstract][Full Text] [Related]
3. Monitoring ovarian cancer using urine cyclic GMP. A two-centre study.
Turner GA; Greggi S; Guthrie D; Benedetti Panici P; Ellis RD; Scambia G; Mancuso S
Eur J Gynaecol Oncol; 1990; 11(6):421-7. PubMed ID: 1964900
[TBL] [Abstract][Full Text] [Related]
4. Urine cyclic nucleotide concentrations in cancer and other conditions; cyclic GMP: a potential marker for cancer treatment.
Turner GA; Ellis RD; Guthrie D; Latner AL; Monaghan JM; Ross WM; Skillen AW; Wilson RG
J Clin Pathol; 1982 Aug; 35(8):800-6. PubMed ID: 6286732
[TBL] [Abstract][Full Text] [Related]
5. Cyclic GMP in urine to monitor the response to ovarian cancer to therapy.
Turner GA; Ellis RD; Guthrie D; Latner AL; Ross WM; Skillen AW
Br J Obstet Gynaecol; 1982 Sep; 89(9):760-4. PubMed ID: 6288064
[TBL] [Abstract][Full Text] [Related]
6. Tumour cell activity markers in epithelial ovarian cancer: are biochemical and cytometric indices complementary?
Redman CW; Finn C; Ward K; Kelly K; Buxton EJ; Varma R; Shortland-Webb W; Luesley DM
Br J Cancer; 1990 May; 61(5):755-8. PubMed ID: 2159769
[TBL] [Abstract][Full Text] [Related]
7. Urinary cyclic adenosine 3',5'-monophosphate (cAMP) and cyclic guanosine 3',5'-monophosphate (cGMP) in asthmatic and normal children.
König P; Carpenter M; White AA
Eur J Respir Dis; 1980 Aug; 61(4):218-26. PubMed ID: 6258958
[TBL] [Abstract][Full Text] [Related]
8. Urinary levels of cyclic guanosine monophosphate (cGMP) in patients with cancer of the uterine cervix: a valuable prognostic factor of clinical outcome?
Orbo A; Jaeger R; Sager G
Eur J Cancer; 1998 Aug; 34(9):1460-2. PubMed ID: 9849432
[TBL] [Abstract][Full Text] [Related]
9. Plasma nitric oxide, endothelin-1 and urinary nitric oxide and cyclic guanosine monophosphate levels in hypertensive pregnant women.
Baksu B; Davas I; Baksu A; Akyol A; Gulbaba G
Int J Gynaecol Obstet; 2005 Aug; 90(2):112-7. PubMed ID: 16005006
[TBL] [Abstract][Full Text] [Related]
10. Urinary excretion of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate in malignancy.
Gennari C; Francini G; Galli M; Lore F
J Clin Pathol; 1978 Aug; 31(8):735-41. PubMed ID: 211147
[TBL] [Abstract][Full Text] [Related]
11. [The value of determination of urine cAMP and cGMP in the diagnosis and predicting the therapeutic effect of malignant ovarian tumors].
Wu XH; Zhang JG
Zhonghua Fu Chan Ke Za Zhi; 1991 May; 26(3):162-5, 188. PubMed ID: 1651834
[TBL] [Abstract][Full Text] [Related]
12. Urinary excretion of cyclic guanosine 3'.5'-monophosphate in children with malignant tumours.
Puschendorf B; Grunicke H; Jentsch J; Berger H
J Clin Chem Clin Biochem; 1981 Sep; 19(9):979-81. PubMed ID: 6270232
[TBL] [Abstract][Full Text] [Related]
13. Urinary cyclic nucleotides and the cytopathology of human uterine cervical dysplasias.
Duttagupta C; Romney SL; Palan PR; Slagle NS
Cancer Res; 1982 Jul; 42(7):2938-43. PubMed ID: 6282452
[TBL] [Abstract][Full Text] [Related]
14. Elevated plasma and urinary guanosine 3':5'-monophosphate and increased production rate in patients with neoplastic diseases.
Chawla RK; Shlaer SM; Lawson DH; Murray TG; Schmidt F; Shoji M; Nixon DW; Richmond A; Rudman D
Cancer Res; 1980 Nov; 40(11):3915-20. PubMed ID: 6258769
[TBL] [Abstract][Full Text] [Related]
15. Magnesium sulfate therapy in preeclampsia is associated with increased urinary cyclic guanosine monophosphate excretion.
Barton JR; Sibai BM; Ahokas RA; Whybrew WD; Mercer BM
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 1):931-4. PubMed ID: 1329514
[TBL] [Abstract][Full Text] [Related]
16. Urinary cyclic GMP after treatment of gynecological cancer. A prognostic marker of clinical outcome.
Orbo A; Hanevik M; Jaeger R; Van Heusden S; Sager G
Anticancer Res; 2007; 27(4C):2591-6. PubMed ID: 17695420
[TBL] [Abstract][Full Text] [Related]
17. Circadian rhythms in the urinary excretion of cyclic 3',5'-adenosine monophosphate (cyclic AMP) and cyclic 3',5'-guanosine monophosphate (cyclic GMP) in human subjects.
Kopp L; Lin T; Tucci JR
J Clin Endocrinol Metab; 1977 Apr; 44(4):673-80. PubMed ID: 191467
[TBL] [Abstract][Full Text] [Related]
18. Urinary excretion of cyclic guanosine 3':5'-monophosphate and cyclic adenosine 3':5'-monophosphate in rats bearing transplantable liver and kidney tumors.
Criss WE; Murad F
Cancer Res; 1976 May; 36(5):1714-6. PubMed ID: 178429
[TBL] [Abstract][Full Text] [Related]
19. Urinary cGMP as biological marker of the renal activity of atrial natriuretic factor.
Wong KR; Xie MH; Shi LB; Liu FY; Huang CL; Gardner DG; Cogan MG
Am J Physiol; 1988 Dec; 255(6 Pt 2):F1220-4. PubMed ID: 2849318
[TBL] [Abstract][Full Text] [Related]
20. Urinary cyclic guanosine 3',5'-monophosphate and cyclic adenosine 3',5'-monophosphate changes in spontaneous and induced onset active labor.
Chen DC; Yuan SS; Su HY; Lo SC; Ren SS; Wu GJ
Acta Obstet Gynecol Scand; 2005 Nov; 84(11):1081-6. PubMed ID: 16232176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
